Bausch + Lomb Corporation
BLCOBausch + Lomb Corporation is a global eye health company specializing in the development, manufacturing, and marketing of pharmaceutical and device-based products for eye care. Founded in 1853, the company offers a range of products including contact lenses, lens care solutions, ophthalmic pharmaceuticals, and surgical instruments, serving eye care professionals and consumers worldwide.
Company News
Silver Point Capital initiated a new $38.7 million stake in Bausch + Lomb, representing 2.8% of its U.S. equity portfolio. Despite being 16% below its IPO price, the company showed 7% revenue growth in Q3 and maintains operational stability.
Browning West, a major shareholder, criticized Cooper Companies for underperformance, weak governance, and misaligned capital allocation strategies across its CooperVision and CooperSurgical divisions.
Global contact lenses market projected to grow from $14.78 billion in 2024 to $29.35 billion by 2034, driven by technological innovations, rising vision health awareness, and integration of AR/VR technologies.
Bausch + Lomb reported $1.22 billion in revenue for Q2 2024, a 17.5% year-over-year increase. EPS was $0.13, down from $0.18 a year ago. The company's performance was mixed, with some business segments exceeding expectations while others fell short.
